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The nucleocapsid protein (N protein) has been found to be an antigenic protein
in a number of coronaviruses. Whether the N protein in severe acute respiratory
syndrome-associated coronavirus (SARS-CoV) is antigenic remains to be eluci-
dated. Using Western blot and Enzyme-linked Immunosorbent Assay (ELISA),
the recombinant N proteins and the synthesized peptides derived from the N pro-
tein were screened in sera from SARS patients. All patient sera in this study
displayed strong positive immunoreactivities against the recombinant N proteins,
whereas normal sera gave negative immunoresponses to these proteins, indicat-
ing that the N protein of SARS-CoV is an antigenic protein. Furthermore, the
epitope sites in the N protein were determined by competition experiments, in
which the recombinant proteins or the synthesized peptides competed against the
SARS-CoV proteins to bind to the antibodies raised in SARS sera. One epitope
site located at the C-terminus was confirmed as the most antigenic region in this
protein. A detailed screening of peptide with ELISA demonstrated that the amino
sequence from Codons 371 to 407 was the epitope site at the C-terminus of the N
protein. Understanding of the epitope sites could be very significant for developing
an effective diagnostic approach to SARS.
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Introduction
Recently several lines of evidence have demonstrated
that a new strain of coronaviruses, SARS-CoV (severe
acute respiratory syndrome-associated coronavirus),
is the pathogen of SARS (1 , 2 ). Within a short pe-
riod, SARS-CoV was decoded completely, providing
a fundamental basis for understanding its pathogene-
sis and developing effective diagnostic and therapeu-
tic approaches (3 − 5 ). However, although the initial
SARS outbreak has ended, people still have quite a
limited knowledge about this infectious disease (6 ).
Worries about the recurrence of SARS in this win-
ter have been expressed by medical professionals and
how to diagnose cases in the early stages of infection
is their major concern. To develop a sensitive assay




for detecting the diluted virus in body fluid, we must
first address the questions about which biological
roles the SARS-CoV structural proteins play and the
strength of the immunoresponses caused by these pro-
teins.
Of all the coronaviral structural proteins, the N
protein is the most abundant throughout infection,
both in mRNA and protein levels (7 ). Compared to
the mRNA levels of other structural genes, the mRNA
of the N protein is expressed three to ten times higher
at 12-hour post-infection (8 ). The N protein has a
high composition of polar amino acid residues. Most
of them display hydrophilicity and immunogenicity,
as, for example, the murine coronavirus (MCV; ref.
9 ), the turkey coronavirus (TCV; ref. 10 ), and the
infectious bronchitis virus (IBV; ref. 11 ). In contrast
to other SARS-CoV structural proteins that contain
multiple sites for glycosylation during infection, which
may cause different immunoresponses, the N protein
is free of glycosylation sites and does not change
its immunological characteristics even expressed in a
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prokaryote system (12 ). Importantly, the SARS-CoV
N protein is highly conserved with an almost com-
plete identity among various strains that have been
sequenced so far (5 ). These features make the N pro-
teins useful for group-specific serologic assays. For
example, the N gene in IBV was expressed in bacte-
ria with a histidine tag at the N-terminus, and the
expressed IBV N protein was then used as antigen
for developing an assay to detect IBV-specific anti-
body. Collisson et al. found that this antigen could
be successfully applied to diagnose IBV viruses in dif-
ferent chicken strains (13 ). Utilizing the baculovirus
expression system, the TCV N protein was expressed
and applied to specific serologic tests for detecting
TCV antibodies in turkeys (14 ). A high degree of
concordance was observed between the ELISA and
the indirect fluorescent antibody (IFA) test with 96%
of specificity (14 ). Therefore, studying the immuno-
genic properties of the N protein may form the basis
for developing immunodetection assays of SARS, and
also for formulating strategies of future vaccine devel-
opment against this disease.
The present study was undertaken to explore the
epitope sites located in the SARS-CoV N protein. We
have generated three different lengths of the N pro-
tein fragments and synthesized nine peptides derived
from the N proteins. We observed that all recombi-
nant proteins could cross-react with the antibodies in
SARS sera. To define the antigenic site(s) on the N
protein, we further screened the synthesized peptides
in SARS sera using Western blot as well as ELISA.
The data obtained from these immunoassays demon-
strated that an epitope site is within the C-terminus
of the N protein.
Results
PCR amplification and expression con-
structs
To amplify the N gene fragments, we used the cDNA
reverse-transcripted from SARS-CoV mRNA as the
template, and three pairs of primers, N-full, ∆N256
and ∆N124, as primers in PCR reactions. As shown
in Figure 1, the sizes of PCR products coincide well
with the theoretical estimation based upon the ge-
nomic sequence, 1.2 Kb, 490 bp, and 890 bp, for
N-full, ∆N256, and ∆N124, respectively. Since all
primers contain additional BamH I site at 5′ end
and Not I at 3′ end, both restriction enzymes were
used to completely digest these PCR products and
pET30a vector. The digested and harvested N gene
fragments were ligated with the linearized pET30a to
form the expression vectors, pET30-N-full, pET30-
∆N256 and pET30-∆N124. In Figure 1, the diges-
tion of these vectors with BamH I and Not I gener-
ated three DNA fragments with different molecular
weights, which were identical to the PCR products,
indicating that these N gene fragments were inserted
into pET30a correctly. Finally all insertions were con-
firmed by DNA sequencing (data not shown).
Fig. 1 Generation of pET30-N expression vectors. A, B, and C represent the experimental process to generate three
expression vectors, pET30-N-full, pET30-∆N124 and pET30-∆N256, respectively. 1. DNA ladder; 2. N fragments
amplified by PCR; 3. pET30a vector; 4. pET30a-N vectors; 5. N fragments generated by restriction digestion of
pET30a-N vectors.
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Expression and purification of recombi-
nant N proteins
The three expression vectors were transformed into
the BL-21 strain and the proteins were expressed
by inducement of IPTG. Interestingly, pET30-∆N124
was able to produce some recombinant proteins even
without the inducement of IPTG, whereas pET30-
N-full and pET30-∆N256 only generated their pro-
teins after the presence of IPTG. According to the hy-
drophobic analysis, the N protein contains several hy-
drophilic regions spanning the whole N protein (Fig-
ure 2). Thus, these recombinant proteins were ex-
pected to be highly soluble. On the contrary, all the
three recombinant proteins expressed in BL-21 mainly
formed inclusion body and released limited soluble
forms in cytoplasm. The recombinants could not be
purified directly from soluble fractions. To obtain a
high protein yield, the bacterial pellets were treated
with 8 M urea followed by a strong probe sonication.
The denatured proteins retained the affinity to Ni2+,
and hence Ni-NTA column was effectively applied into
the purification of these recombinants. As shown in
Figure 3, high purity proteins from all the three N
recombinants have been obtained through one step of
affinity chromatography (>95%).
Fig. 2 Hydropathy plot of the SARS-CoV N protein.
Fig. 3 SDS-PAGE analysis of expression and purification of the recombinant N proteins. A, B, and C represent the
experimental process to express or purify the recombinant proteins, N-full, ∆N124 and ∆N256, respectively. 1. Protein
ladder; 2. empty vector, pET30a, in BL-21 without inducement; 3. empty vector, pET30a, in BL-21 with inducement;
4. expression vectors, pET30a-Ns, in BL-21 without inducement; 5. expression vectors, pET30a-Ns, in BL-21 with
inducement; 6. the purified N recombinants.
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Immunoresponses of the recombinant N
proteins to SARS sera
The lysate of Vero-E6 infected by SARS-CoV was
tested by Western blot with SARS sera as the pri-
mary antibody. An obvious immunoprecipitate band
appeared around 50 kDa (Figure 4A), close to the
molecular weight of the N protein based upon the
theoretical estimation. The same experiments were
repeated with eleven sera from SARS patients, giv-
ing a consistent result that a major immunoreactive
band is located at about 50 kDa (data not shown).
To check the immunoreactions of the recombinant N
proteins, all were examined by Western blot using the
sera from SARS patients. Figure 4B depicts that all
three N recombinants have strong immunoresponses
to the SARS sera. Impressively, the size of the N-
full protein is almost identical to this immuno-positive
band found from Vero-E6 lysate. Thus, the evidence
supports the conclusion that the N protein expressed
from Vero-E6 cells that had been infected by SARS-
CoV is an antigenic protein. Another potentially im-
portant phenomenon is that the immunoreactive in-
tensities of three recombinant proteins are quite simi-
lar. The N-full protein contains the whole amino acid
sequence of the N protein. However, the other two re-
combinants, ∆N256 and ∆N124, are truncated N pro-
teins. The ∆N256 protein only has 166 amino acids at
the C-terminus of the N protein, whereas the ∆N124
protein is lack of 124 amino acids at the N-terminus
of the N protein but contains 298 amino acids at C-
terminus. Hence, all of the N recombinants share
the same C-terminus and are distinguished from each
other by the lengths of their N-terminus. Since sim-
ilar immunoreactivities were observed in the three N
recombinants, they may share similar epitope site(s),
possibly within 166 amino acids at the C-terminus
that are shared by the three recombinants. The N
proteins, with the truncated N-terminus ∆N256 and
∆N124, did not seem to lose their immunoresponses
to SARS sera, indicating that the antigenicity of N-
terminus of the N protein might be much weaker than
that of the C-terminus. This hypothesis was sup-
ported by ELISA experiments. A number of SARS
sera were tested by ELISA to examine the immunore-
activities of these N recombinants, and all the three N
proteins displayed similar positive ELISA reactivities
(data not shown).
Fig. 4 Immunoassays for the infected Vero-E6 cell lysate and the recombinant N proteins by Western blot. A. Western
blot analysis of the Vero-E6 lysate infected by SARS-CoV using SARS sera as primary antibody: 1. protein ladder;
2. Vero-E6 cells infected by SARS-CoV (the N protein band is obvious); 3. Vero-E6 cells uninfected by SARS-CoV.
B. Western blot analysis of the N recombinants using SARS sera as primary antibody: 1. protein ladder; 2, 3, 4, the
recombinant N proteins, ∆N256, ∆N124 and N-full, respectively, stained by Coomassie blue; 5, 6, 7, the recombinant
N proteins, ∆N256, ∆N124 and N-full, respectively, immunostained in Western blot using SARS serum as primary
antibody.
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Screening the epitope site at the C-
terminus of the N protein
Having established that the three N recombinants
share 166 amino acids of the N protein at the C-
terminus and share similar immunoresponses to SARS
sera, the next question to address is how to precisely
localize the epitope site(s) within this region. On the
basis of hydropathy plot, nine peptides located in this
region were selected and synthesized. These synthe-
sized peptides were screened in SARS sera (31 cases)
with ELISA. The lysate of infected Vero-E6 cells was
used as positive control for ELISA reactivity. A pep-
tide showing comparable ELISA reactivity with this
control would be considered as an immunoreactive N
fragment. Table 1 summarizes the ELISA data from
the screening of the nine peptides, in which p val-
ues are very important, indicating whether there is
a significant difference in ELISA reactivities between
a synthesized peptide and SARS-CoV as the antigen.
Two peptides, N371 and N385, have comparable im-
munoreactivities with the Vero-E6 lysate, with 97%
and 94% positive detection rates, respectively. Thus
the epitope site at the C-terminus of the N protein is
likely to be located at Codons 371-407.
Table 1 The Statistics of ELISA Reactivity [optical density/cut-off (OD/CO)] in SARS Patients’ Sera
Peptides Sequence Position Hydrophilicity OD/CO (n=31) p values
SARS-CoV 4.23± 1.85
N177 SRGGSQASSRSSSRSRGNSRNS 177− 198 + 0.93± 0.97 <0.05
N196 RNSTPGSSRGNSPARMASGGGE 196− 217 + 0.48± 0.60 <0.05
N215 GGETALALLLLDRLNQLESKVSGKG 215− 239 − 2.10± 2.30 <0.05
N245 QTVTKKSAAEASKKPRQKRTATKQ 245− 268 + 2.05± 1.59 <0.05
N258 KPRQKRTATKQYNVTQAFGRRG 258− 279 + 0.78± 1.01 <0.05
N355 NKHIDAYKTFPPTEPKKDKKKK 355− 376 + 2.17± 1.93 <0.05
N371 KDKKKKTDEAQPLPQRQKKQ 371− 390 + 4.36± 2.61 NS
N385 QRQKKQPTVTLLPAADMDDFSRQ 385− 407 + 3.44± 2.56 NS
N401 MDDFSRQLQNSMSGASADSTQA 401− 422 + 1.36± 2.35 <0.05
The significance of the differences (p) in ELISA reactivities to SARS-CoV and the different synthesized peptides was
analyzed by the Student’s t-test.
Confirming N371 at epitope site by
competitive inhibition using ELISA and
Western blot
Since the antibodies in sera from SARS patients can
recognize these viral proteins, the synthesized pep-
tides, if they indeed mimic some epitope sites in this
virus, should elicit immunoresponses and neutralize
the immunoreaction in ELISA. Peptide N371 is the
most comparable antigen among the nine synthesized
peptides. Hence, it is deduced to be a good competi-
tor against SARS-CoV virus for antibody binding, if
it does exist at the epitope site. Prior to ELISA deter-
minations, peptide N371 was incubated with or with-
out SARS serum for 30 min, respectively, and was
then added to a microtiter plate coated with the ex-
tracted proteins from SARS-CoV. As predicted, the
ELISA reactivities were attenuated with the increase
of peptide concentrations in the SARS sera (Figure
5A). Furthermore, the competition experiments were
conducted in Western blot. The PVDF (Polyvinyli-
dene Fluoride) membrane transblotted with three re-
combinant N proteins were incubated with the SARS
serum containing the peptide, N371. Compared with
the immunoresponses showed in Figure 3B, the cross-
reactions between the recombinants and SARS an-
tibodies were significantly curtailed, indicating that
this peptide inhibited the recognition between SARS-
CoV and its antibodies (Figure 5B). This peptide,
therefore, is confirmed to be an epitope site that ex-
ists in SARS-CoV as well as in the three recombinant
proteins.
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Fig. 5 Competition experiments to confirm the role of N371 at epitope site in the N protein. A. Competition
experiment in ELISA with peptide N371. Prior to ELISA, the serum from SARS patient was incubated with peptide
N371 in different concentrations. The serum with the peptide was incubated with the infected Vero-E6 cells, which
were coated on microtiter plates, and the immunoreactivities were measured by ELISA as described in Methods. The
competition experiment at each concentration was parallelly tested for four times. B. Competition experiment in
Western bolt with peptide N371. Prior to Western blot, the serum from SARS patient was incubated with peptide
N371 at concentration of 9 µg/mL. The serum with the peptide was incubated with the PVDF membrane transblotted
with the recombinant N proteins, and the immunoprecipitation was monitored by color development using a substrate
mixture of NBT and BCIP. 1. N-full; 2. ∆N124; 3. ∆N256; 4. protein ladder.
Discussion
Antigenicity of the N proteins in the coronavirus fam-
ily has been extensively studied (15 , 16 ). Usually
these N proteins contain multiple epitopic sites. How-
ever, they commonly have an epitopic site at the C-
terminus. For instance, the epitope sites for TGEV
(transmissible gastroenteritis virus), MHV (mouse
hepatitis virus), and IBV are located around Codons
360-382 (17 ), 381-405 (18 ), and 360-409 at C-termini
(19 ), respectively. Similar to other coronaviruses,
the present study has confirmed that an antigenic
site is located at the C-terminus of SARS-CoV. In
Figure 2, there is a hydropathy plot for the SARS-
CoV N protein. A lot of regions in this protein have
low hydrophobicity scores (<0), and the C-terminus
is specifically strong in hydrophilicity. Two major
forces, charge-charge interactions and hydrogen bonds
caused by hydrophilicity, have been hypothesized to
be crucial for the formation of epitope site. Peptides
N371 and N385 are both located at the hydrophilic
region of C-terminus and contain a high content of
polar amino acids (∼ 38%). Further more, their bio-
physical parameters correlated well with the values
of ELISA reactivity as well as the intensity of West-
ern blot when the two peptides were used as antigens.
These findings, thus, support the theory that both
hydrophilicity and peptide charge are important in
determining immunoactive sites in SARS-CoV N pro-
teins.
As described above, the N protein of SARS-CoV
is hydrophilic and chargeable. The major function of
the N protein in coronaviruses is to stabilize genomic
RNA by forming a helical ribonucleocapsid (RNP),
which is located at the viral core, and is highly sta-
ble under conditions of high ionic strength and highly
resistant to the actions of RNase (20 ). Because of
its location in the virus, the N protein is rarely gly-
cosylated in an infected cell. Hence, its recombinant
proteins should be soluble during expression in the
bacterial system. On the contrary, all the three re-
combinant N proteins did not express in soluble forms
but mainly generated the inclusion bodies. Although
a number of approches were taken to improve the
solubility of these recombinants, such as altering ex-
pression temperature or decreasing inducer concen-
trations, the formations of inclusions were found in
BL-21 strains consistently. Some misfolding mech-
anisms are believed to be behind the phenomenon.
Moreover, this phenomenon may explain the role of
the N protein in the virus because the N protein and
viral genomic RNA interact reciprocally to stabilize
each other. In the bacterial expression system, the
precipitation of the N protein could result from the
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absence of the RNA molecules.
Serological assay is widely used for the diagnosis of
virus infection in the host for its low cost, fast speed
and high accuracy (21 ). In some urgent situations, a
common way in serological assay is to use viral lysates
as antigens. Nevertheless, the use of viral lysates
brings some drawbacks. For instance, people prepar-
ing SARS-CoV lysates are at risk of infection. Instead
of viral lysate, recombinant proteins can be used to
avoid such problems. However, to generate a proper
antigen specific to SARS-CoV is a tough challenge.
A major problem is how to discover high antigenic
fragments in viral proteins. In this study, a specific
epitope site has been identified. Significantly, these
recombinant proteins and synthesized peptides (N371
and N385) were confirmed to have strong immunore-
sponse to the patient sera determined by either ELISA
or Western blot. Screening with a total of 31 SARS
patient and 24 normal samples, these antigens, either
from recombinants or from peptides, have shown a
potential application in clinical diagnosis, with under
2% negative detection rate and over 95% positive de-
tection rate. Therefore, the information provided in
this report regarding the epitope site of the N protein




The E. coli strains, DH5α and BL-21(λCE6), were
purchased from Beijing Dingguo Corporation (Bei-
jing, China). All primers were synthesized by Shang-
hai Ding’an Corporation (Shanghai, China). The bac-
terial protein expression vector, pET-30a, was pur-
chased from Novagen (Darmstadt, Germany). Re-
striction enzymes and nitro-blue tetrazolium chloride
(NBT) and 5-bromo-4-chloro-3′-indolyphosphate p-
toluidine salt (BCIP) were obtained from Promega
(Madison, USA). Taq DNA polymerase and related
PCR reagents were from Invitrogen (Carlsbad, USA).
Ni-NTA resin was purchased from Qiagen (Hilden,
Germany). The antibody anti-human IgG conjugated
with alkaline phosphatase was purchased from Beijing
Zhongshan Company (Beijing, China).
Serum specimens
Sera from SARS patients were from the hospitals
in Beijing, and the control sera were obtained from
healthy volunteers. The clinical diagnostic criteria for
SARS followed the Clinical Description of SARS re-
leased by WHO (http://www.who.int/csr/sars/guide
lines/en/).
Virus resource
The SARS-CoV BJ01 strain used in this study was
cultured by the Microbe Epidemic Institute in the
Academy of Military Medical Sciences (22 ). The
BJ01 genome was sequenced by Beijing Genomics In-
stitute (BGI). All of the N protein fragments were
designed based upon the genome sequence.
SARS-CoV infection and protein ex-
traction from the infected cells
The SARS-CoV was propagated on Vero-E6 cells as
described above at the Microbe Epidemic Institute in
the Academy of Military Medical Sciences. After vi-
ral propagation, the cells were harvested and placed
at 70˚C for 2 h to inactivate the virus. Then, the in-
fected Vero-E6 cells in culture medium were concen-
trated by polyethylene glycol (PEG) 20,000 followed
by cell lysis and protein denaturation with 8 M urea.
The cell lysate was further sonicated with a probe
sonicator and centrifuged at 13,000 g to remove the
insoluble debris. The supernatant was used for West-
ern blot and ELISA determinations.
Peptide design and synthesis
The amino acid sequence of the N protein was down-
loaded into the ProtScale program at Swiss Insti-
tute of Bioinformatics (SIB) to analyze the physical
characteristics of the proteins, such as hydrophilicity,
hydrophobicity, accessible residues, buried residues,
molecular weight, and pI values. A total of nine pep-
tides ranging in size from 16 to 25 amino acid residues
were selected for synthesis. All the peptides were syn-
thesized commercially by Chinese Peptide Corpora-
tion (Hangzhou, China). The synthesized peptides
were characterized by HPLC and mass spectrometry.
Plasmid constructions
The viral genomic RNA was prepared using TRI-
zol reagent (Invitrogen). First-strand cDNA syn-
thesis was carried out by a SuperScript sys-
tem as described in the products manual (In-
vitrogen). Primers for PCR amplification were
synthesized by Shanghai Ding’an Co. The full
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length of the N gene was amplified by PCR us-
ing the primer pair, 3′ primer (ATAAGAATGCG-
GCCGCTTATGCCTGAGTTGAA) with a Not I
restriction site and 5′ primer (CGGGATCCAT-
GTCTGATAATGGACCCCA) with a BamH I site.
To generate the ∆N256 and ∆N124 fragments,
the pairs of the primer were designed as follows.
3′ primer (ATAAGAATGCGGCCGCTTATGCCT-
GAGTTGAA) with a Not I site and 5′ primer
(CGGGATCCCCTCGCCAAAAACGTACT) with a
BamH I site for ∆N256, and 3′ primer (AAGAAT-
GCGGCCGCTTATGCCTGAGTTGAA) with a Not
I site and 5′ primer (CGGGATCCGCTAACAAA-
GAAGGCATCGTA) with a BamH I site for ∆N124.
After restriction digestion, the digestive fragment con-
taining the N gene was ligated with a linearized
pET30a vector (23 ).
Expression and purification of N recom-
binant proteins
Three transformed BL-21 stains containing the ex-
pression vectors, pET30-N-full, pET30-∆N256 and
pET30-∆N124, were inoculated into 500 mL of LB
broth containing 100 µg/mL of kanamycin. Being
shaked, the cultures grew to an optical density (OD)
at 600 nm of 0.6-0.8 at 20˚C, and IPTG was added
to a final concentration of 1 mM. The bacteria were
incubated at 37˚C for additional 4-6 h, and followed
by centrifugation at 4,000 g for 10 min to get the bac-
terial pellets. The pellets were resuspended in a 10-
mL binding buffer containing 20 mM Tris-HCl, pH
7.9, 200 mM NaCl, and 5 mM imidazole, and were
lysed by sonication for 3 min. The resulting lysates
were centrifuged at 12,000 g at 4˚C for 20 min. The
supernatant and pellet were examined by SDS-PAGE
(SDS-PolyAcrylamide Gel Electrophoresis) and West-
ern blot to check the solubility of the expressed pro-
tein. If the inclusion was formed, the bacterial pel-
lets were dissolved in the binding buffer containing 8
M urea. The recombinant proteins were purified by
an affinity chromatography, Ni-NTA (Qiagen), with a
linear elution of imidazole.
Western blot
The recombinant proteins were separated by SDS-
PAGE (10%) and transferred onto PVDF membranes.
The membranes were blocked by 3% BSA in Tris 100
mM, NaCl 120 mM, 0.1% Tween-20, pH 7.9 (TTBS),
and then were incubated with sera from SARS pa-
tients as primary antibody. An anti-human IgG con-
jugated with alkaline phosphatase was used as the sec-
ond antibody. The immunoprecipitated bands were
developed using a substrate mixture of NBT and
BCIP.
ELISA measurement
ELISA tests were carried out according to conven-
tional protocol. In brief, the purified fusion pro-
tein was mixed with the sample dilution buffer, em-
bedded in 96-well ELISA plates, and incubated at
37˚C for 30 min. Then the wells were washed for
five times with the washing buffer, and incubated
with sera from SARS patients or normal controls.
Each well was washed and incubated with peroxidase-
conjugated goat anti-human IgG at 37˚C for 20 min.
Finally the wells were washed again with PBS con-
taining 0.5% Tween-20. The peroxidase reaction was
visualized using the o-pheylenediamine solution as
substrate. After 10 min of incubation at 37˚C, the re-
action was stopped by adding 50 µL of 4 M sulphuric
acid, and OD at 450 nm with a reference wavelength
of 630 nm was measured by using an automatic ELISA
plate reader (Multiskan Microplate Photometer, Fin-
land).
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